ranibizumab (Lucentis)
ranibizumab is an FDA-licensed reference biologic from Genentech, Inc., with 3 approved follow-on biologics.
Reference product
Lucentis ranibizumab
Genentech, Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CDER
- Patents
- 11 listed
Exclusivity & patent cliffs
Reference approval
Approval date of the reference ranibizumab product.
10 yr 1 mo ago
Patent 6,716,602 expires
Published Purple Book patent expiration.
4 yr 11 mo ago
Patent 6,828,121 expires
Published Purple Book patent expiration.
4 yr 3 mo ago
Patent 9,688,775 expires
Published Purple Book patent expiration.
3 yr 9 mo ago
Patent 6,921,659 expires
Published Purple Book patent expiration.
3 yr ago
Patent 8,383,773 expires
Published Purple Book patent expiration.
2 yr 10 mo ago
Patent 8,574,869 expires
Published Purple Book patent expiration.
in 1 yr 10 mo
Patent 10,421,984 expires
Published Purple Book patent expiration.
in 7 yr 1 mo
Patent 9,765,379 expires
Published Purple Book patent expiration.
in 7 yr 7 mo
Patent 10,017,732 expires
Published Purple Book patent expiration.
in 7 yr 7 mo
Patent 10,829,732 expires
Published Purple Book patent expiration.
in 7 yr 7 mo
Patent 10,112,994 expires
Published Purple Book patent expiration.
in 9 yr 3 mo
Biosimilars & interchangeables for ranibizumab
Published patents
| Patent | Expires | In |
|---|---|---|
| 6,716,602 | 4 yr 11 mo ago | |
| 6,828,121 | 4 yr 3 mo ago | |
| 9,688,775 | 3 yr 9 mo ago | |
| 6,921,659 | 3 yr ago | |
| 8,383,773 | 2 yr 10 mo ago | |
| 8,574,869 | in 1 yr 10 mo | |
| 10,421,984 | in 7 yr 1 mo | |
| 9,765,379 | in 7 yr 7 mo | |
| 10,017,732 | in 7 yr 7 mo | |
| 10,829,732 | in 7 yr 7 mo | |
| 10,112,994 | in 9 yr 3 mo |
ranibizumab: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for ranibizumab.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
